scholarly journals EFFECTS OF FIXED DOSE COMBINATION AZILSARTAN MEDOXOMIL/CHLORTALIDONE ON THE CENTRAL BP IN HYPERTENSIVE PATIENTS WITH HFPEF

2021 ◽  
Vol 39 (Supplement 1) ◽  
pp. e373
Author(s):  
Khyadi Gudieva ◽  
Vadim Medovschikov ◽  
Nurlan Eshniyazov ◽  
Alina Kravchenko ◽  
Ayten Safarova ◽  
...  
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Hypertensive Patients ◽  
Dose Combination ◽  
Azilsartan Medoxomil

scholarly journals Efficacy and safety of azilsartan medoxomil/chlortalidone fixed-dose combination in hypertensive patients uncontrolled on azilsartan medoxomil alone: A randomized trial

2018 ◽  
Vol 20 (10) ◽  
pp. 1473-1484 ◽  
Author(s):  
David J. Collier ◽  
Attila Juhasz ◽  
Enrico Agabiti-Rosei ◽  
Eric Lloyd ◽  
Michie Hisada ◽  
...  
Keyword(s):  
Randomized Trial ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Efficacy And Safety ◽  
Hypertensive Patients ◽  
Dose Combination ◽  
Azilsartan Medoxomil

scholarly journals Efficacy and Safety of a Lercanidipine/Enalapril Fixed-Dose Combination in Hypertensive Patients in Portugal

Drugs in R&D ◽  
2014 ◽  
Vol 14 (2) ◽  
pp. 147-154 ◽  
Author(s):  
João Maldonado ◽  
Telmo Pereira ◽  
Alfredo Tavares
Keyword(s):  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Efficacy And Safety ◽  
Hypertensive Patients ◽  
Dose Combination

scholarly journals A ramipril versus ramipril/amlodipin fix kombináció egyéves perzisztenciája hypertoniás betegekben

2017 ◽  
Vol 158 (42) ◽  
pp. 1669-1673 ◽  
Author(s):  
Gábor Simonyi ◽  
Tamás Ferenci
Keyword(s):  
Blood Pressure ◽  
Survival Analysis ◽  
Combination Therapy ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Hypertensive Patients ◽  
Persistence Rate ◽  
Dose Combination ◽  
One Year ◽  
The One

Abstract: Introduction: In the treatment of hypertension avoiding adverse cardiovascular complications to achieve target blood pressure is essential. The appropriate drug selection, and if necessary to change to combination therapy, patients adherence is important which may help fixed dose combination. Aim: The aim of the authors was to investigate the one year adherence of the ramipril and ramipril/amlodipine fixed dose combination in hypertensive patients. Method: Prescriptions database of the National Health Insurance Fund in Hungary on pharmacy-claims was analysed between October 1, 2012 and September 30, 2013. The authors identified patients who filled prescriptions for ramipril monotherapy and fixed dose combinations of ramipril/amlodipine prescribed for the first time in hypertensive patients who have not received similar drugs in the previous year. To model the adherence, the apparatus of survival analysis was used, where “survival” was the time to abandon the medication. As it was available to month precision, discrete time survival analysis was applied: a generalized linear model was estimated with complementary log-log link function with the kind of drug being the only explanatory variable. Results: 92,546 patients met the inclusion criteria. During the trial period, ramipril therapy or ramipril/amlodipine fixed dose combination was started in 82,251 and 10,295 patients, respectively. One year persistence rate in patients with ramipril was 30% and 54% in patients with ramipril/amlodipine fixed dose combination therapy. Considering only the 360-day study period, the mean duration of persistence was 189.9 days in patients on ramipril and 270.6 days on ramipril/amlodipine fixed dose combination therapy. The hazard of discontinuation was more than twofold higher during treatment with ramipril compared with the use of the ramipril/amlodipine fixed dose combination therapy (HR = 2.11 [95% CI: 2.05–2.17], p<0,001). Conclusions: There is a significant difference between the one year persistence of ramipril and ramipril/amlodipine fixed dose combination therapy in hypertension. The result demonstrated that ramipril/amlodipine fixed dose combination therapy has a better one year persistence rate. When the next step is necessary to achieve target blood pressure, ramipril/amlodipine fixed dose combination therapy is preferable. Orv Hetil. 2017; 158(42): 1668–1673.

scholarly journals First-Step Use of Fixed-Dose Combination Treatment in Stage 2 Hypertensive Patients: Has the Time Come?

2007 ◽  
Vol 9 (4) ◽  
pp. 276-284
Author(s):  
Michael A. Weber ◽  
Luis Ruilope ◽  
Thomas D. Giles ◽  
Joseph L. Izzo
Keyword(s):  
Combination Treatment ◽  
Fixed Dose Combination ◽  
Fixed Dose ◽  
Hypertensive Patients ◽  
Dose Combination
Sign in / Sign up

Export Citation Format

Share Document